In a new publication, SNF Institute investigators Jeff Ravetch and Stylianos Bournazos found that in humans, the antibodies elicited by their new vaccine candidate rely on interactions with specific immune receptors known to give protection against viral diseases. These findings are consistent with their previous findings. Knowing this helps us get closer to designing universal flu vaccines with maximal effect.